Investing Profile

Richard Heyman

InvestorVC
Venture Partner at ARCH Venture Partners
Photo of Richard Heyman, Venture Partner at ARCH Venture Partners

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
cb
ARCH Venture Partners Venture Partner
$50K - $150.0M
$25.0M
$635.8M
Chairperson of the Board RayzeBio2022 - Present
Board of Director and Scientific Advisory Board Member Curebound2021 - Present
BOD Member/Chairman Enliven Therapeutics2020 - Present
Board of Managers Life Science Cares San Diego2020 - Present
Chairman of the Board PMV Pharmaceuticals, Inc.2020 - Present
Venture Partner ARCH Venture Partners2020 - Present
Chairman/BOD member Vividion Therapeutics, Inc.2018 - Present
Vice Chairman of The Board of Trustees Salk Institute for Biological Studies2015 - Present
Chairman of the BOD Aragon Pharmaceuticals2014 - Present
Executive Chairman Metacrine Inc.2015 - 2022
Chairperson of the Board Amunix Pharmaceuticals2019 - 2021
BOD Member Yumanity Therapeutics2016 - 2021
BOD Member Gritstone Oncology2015 - 2021
President and CEO Seragon Pharmaceuticals2013 - 2015
President and CEO Aragon Pharmaceuticals2009 - 2013
Chief Scientific Officer Kalypsys, Inc.2006 - 2008
Sr. Vice President Exelixis, Inc.2004 - 2006
CSO X-Ceptor Therapeutics1999 - 2006
VP Research Ligand Pharmaceuticals1990 - 1999
Postdoctoral Fellow Salk Institute1986 - 1990
University of Minnesota PhD Pharmacology